Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, Dufek M, Saubadu S, Bejuit R, Truffinet P, Djukic B, Wallstroem E, Giovannoni G; Frexalimab Phase 2 Trial Group. Vermersch P, et al. N Engl J Med. 2024 Feb 15;390(7):589-600. doi: 10.1056/NEJMoa2309439. N Engl J Med. 2024. PMID: 38354138 Clinical Trial.
Corrigendum to "The measured CSF/plasma donepezil concentration ratio but not individually measured CSF and plasma concentrations significantly increase over 24 h after donepezil treatment in patients with Alzheimer's disease" [Biomed. Pharmacother. 159 (2023) 114223].
Valis M, Dlabkova A, Hort J, Angelucci F, Pejchal J, Kuca K, Pavelek Z, Karasova JZ, Novotny M. Valis M, et al. Among authors: pavelek z. Biomed Pharmacother. 2023 Sep;165:115226. doi: 10.1016/j.biopha.2023.115226. Epub 2023 Jul 28. Biomed Pharmacother. 2023. PMID: 37516593 Free article. No abstract available.
Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries.
Hrnciarova T, Drahota J, Spelman T, Hillert J, Lycke J, Kubala Havrdova E, Recmanova E, Adamkova J, Mares J, Libertinova J, Pavelek Z, Hradilek P, Ampapa R, Stetkarova I, Peterka M, Martinkova A, Stourac P, Grunermelova M, Vachova M, Dufek M, Horakova D. Hrnciarova T, et al. Among authors: pavelek z. Mult Scler Relat Disord. 2023 Aug;76:104803. doi: 10.1016/j.msard.2023.104803. Epub 2023 Jun 12. Mult Scler Relat Disord. 2023. PMID: 37329786
The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 2021.
Stastna D, Drahota J, Lauer M, Mazouchova A, Menkyova I, Adamkova J, Ampapa R, Dufek M, Grunermelova M, Hradilek P, Kubala Havrdova E, Mares J, Martinkova A, Pavelek Z, Peterka M, Recmanova E, Rockova P, Stetkarova I, Stourac P, Vachova M, Horakova D. Stastna D, et al. Among authors: pavelek z. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2023 Apr 28. doi: 10.5507/bp.2023.015. Online ahead of print. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2023. PMID: 37114703
35 results